Division of Solid Tumor Oncology

The Gastrointestinal Oncologic Group is led by Steven J. Cohen, MD.  Dr. Cohen has extensive experience in all phases of clinical trials across multiple GI malignancies. Our program, focuses on providing state of the art treatments for patients with a variety of primary gastrointestinal cancer types, including pancreatic cancer, liver and biliary cancers, colon and rectal cancers, esophageal cancer, stomach cancer, and neuroendocrine tumors.  Dr. Cohen continues to set the standard with his efforts working to develop national programs and procedures through his leadership within the NCI (National Cancer Institute).  Another member of the GU team, Atrayee Basu Mallick, MD  serves as the Enterprise Director of the Bone and Soft Tissue Sarcoma Center at Jefferson, leading a multidisciplinary team of oncologists, surgeons, radiologists, pathologists, and supportive care providers. With a focus on personalized, patient-centered treatment, Dr. Mallick ensures that each patient is actively involved in their care decisions, including access to cutting-edge clinical trials. The program leverages advanced diagnostic technologies for precise staging and treatment planning, crucial for managing sarcomas. Dr. Mallick is dedicated to providing compassionate, comprehensive care, recognizing that each patient’s journey is unique.  The GI program contines to develop treatment options as part of our multidisciplinary team, leveraging ideas and specialists from medical oncology, surgery, radiation oncology, and interventional radiology.  At the forefront of our clinical care is translational research. This type of research is aimed at solving particular problems, but applies accross the spectrum of science.. 

Treatment of gastrointestinal cancer varies depending on a patients type and stage of cancer.  You also have to calculate the patients age, overall health, and other qualifying factors. Here at the Sydney Kimmel Comprehensive Cancer Center, we offer several cancer therapies for our patients.  Daniel Lin, MD, MSc is the Director of our Clinical Outpatient Operations for Medical Oncology and the Medical Director of the Honickman Infusion Center.  Dr. Lin is the Deputy Director of the SKCC Liver Cancer Service Line, where he collaborates with a multidisciplinary team to improve care integration for hepatobiliary cancer patients. Nationally, he chairs the Hepatobiliary Pathway within the ClinicalPath GI Committee, shaping evidence-based treatment pathways for liver and biliary cancers. He works across disciplines to streamline clinic and infusion processes, enhancing operational efficiency and ensuring high-quality patient care.  Specializing in hepatobiliary cancers, Dr. Lin is the Deputy Director of the SKCC Liver Cancer Service Line, where he collaborates with a multidisciplinary team to improve care integration for hepatobiliary cancer patients. Nationally, he chairs the Hepatobiliary Pathway within the ClinicalPath GI Committee, shaping evidence-based treatment pathways for liver and biliary cancers.  As Principal Investigator and Co-Investigator on several clinical trials for GI malignancies, Dr. Lin leads research efforts at Thomas Jefferson University Hospital, focused on improving outcomes for hepatobiliary cancer patients.

We desire to bring the best understanding of how to prevent, treat, and provide advice from relevant discoveries here at Jefferson and across the nation to our patients.  Furthermore, our program offers innovative supportive services to address the complex psychosocial of our patients.

If you are a medical student with a passion for gastrointestinal oncology, clinical research, and innovative treatment strategies, this is an exciting opportunity to work alongside medical oncologist Babar Bashir, MD, MS, an Assistant Professor in the Departments of Medical Oncology and Pharmacology with a clinical focus on treating gastrointestinal (GI) cancers. He also serves as the Director of Early Phase Research Operations and leads the Phase I program at Jefferson, where he plays a pivotal role in advancing novel therapies through clinical trials. As Principal Investigator, Dr. Bashir oversees both industry-sponsored and investigator-initiated clinical trials, giving him an active role in the development of new treatment options for GI malignancies. Dr. Bashir’s translational research interests are focused on the development of novel therapeutic cancer vaccines and CAR-T cell therapies specifically for colorectal cancer. He collaborates closely with basic scientists at Jefferson to bridge laboratory discoveries with clinical applications, aiming to bring cutting-edge treatments to patients in need.  His overarching career goal is to develop innovative treatment options for both early-stage and advanced GI malignancies to improve patient outcomes. Dr. Bashir is also deeply committed to mentorship, aspiring to guide both current and future fellows and faculty in the areas of GI malignancies and clinical research. Here at Jefferson, you will have the chance to engage in cutting-edge research, develop expertise in hepatobiliary malignancies, and contribute to improving patient care through multidisciplinary collaboration.